Thermo Fisher Scientific has reached a definitive agreement to acquire clinical trial endpoint data solutions provider Clario Holdings for $8.875bn in cash upon completion of the deal. Clario will be acquired from a shareholder group spearheaded by Astorg and Nordic Capital, along with Cinven and Novo Holding. Clario is known for integrating endpoint data of the trial from various sources, including clinical sites, subjects, and devices. This integration facilitates biotech and pharmaceutical companies ...